Department of Medicine, Division of Endocrinology, Indiana University, Indianapolis, Indiana, USA.

This email address is being protected from spam bots, you need Javascript enabled to view it

Bone is the most common site for metastasis of advanced prostate cancers. Once housed in the skeleton, tumors are incurable and cause protracted morbidity, and bone metastases may contribute to mortality through unknown mechanisms. Bone provides a unique microenvironment whose local interactions with tumor cells offer novel targets for therapeutic interventions. Many standard cancer treatments cause bone loss, which may aggravate skeletal metastases, although this is preventable with approved agents. Improved bone-targeted treatments can decrease the serious skeletal morbidities associated with metastatic prostate cancer and may in the future improve overall survival. The development of such treatments requires preclinical evaluation in animal models of prostate cancer growth in bone.

Written by:
Mohammad KS, Fournier PG, Guise TA, Chirgwin JM.   Are you the author?

Reference:
Anticancer Agents Med Chem. 2009 Dec 1. Epub ahead of print.

PubMed Abstract
PMID:19719455

UroToday.com Prostate Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!